162 related articles for article (PubMed ID: 37016355)
21. Epidemiology and Economic Burden of von Hippel-Lindau Disease-Associated Renal Cell Carcinoma in the United States.
Jonasch E; Song Y; Freimark J; Berman R; Nguyen H; Signorovitch J; Sundaram M
Clin Genitourin Cancer; 2023 Apr; 21(2):238-247. PubMed ID: 36682891
[TBL] [Abstract][Full Text] [Related]
22. The rate of occurrence, healthcare resource use and costs of adverse events among metastatic non-small cell lung cancer patients treated with first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors.
Subramanian J; Fernandes AW; Laliberté F; Pavilack M; DerSarkissian M; Duh MS
Lung Cancer; 2019 Dec; 138():131-138. PubMed ID: 31733614
[TBL] [Abstract][Full Text] [Related]
23. Direct and Indirect Healthcare Resource Utilization and Costs Among Migraine Patients in the United States.
Bonafede M; Sapra S; Shah N; Tepper S; Cappell K; Desai P
Headache; 2018 May; 58(5):700-714. PubMed ID: 29446063
[TBL] [Abstract][Full Text] [Related]
24. Epidemiology of Rett syndrome in Serbia: prevalence, incidence and survival.
Sarajlija A; Kisic-Tepavcevic D; Nikolic Z; Savic Pavicevic D; Obradovic S; Djuric M; Pekmezovic T
Neuroepidemiology; 2015; 44(1):1-5. PubMed ID: 25571926
[TBL] [Abstract][Full Text] [Related]
25. Health resource utilization and cost before versus after initiation of second-generation long-acting injectable antipsychotics among adults with schizophrenia in Alberta, Canada: a retrospective, observational single-arm study.
Wong KO; Klarenbach SW; Martins KJB; Chue P; Dursun SM; Snaterse M; Guigue A; So H; Luu H; Vu K; Richer L
BMC Psychiatry; 2022 Jul; 22(1):444. PubMed ID: 35780116
[TBL] [Abstract][Full Text] [Related]
26. Healthcare resource utilization and costs in individuals with Huntington's disease by disease stage in a US population.
Exuzides A; To TM; Abbass IM; Ta JT; Patel AM; Surinach A; Fuller RLM; Luo J
J Med Econ; 2022; 25(1):722-729. PubMed ID: 35608039
[TBL] [Abstract][Full Text] [Related]
27. Healthcare Resource Utilization and Costs in Celiac Disease: A US Claims Analysis.
Cappell K; Taylor A; Johnson BH; Gelwicks S; Wang S; Gerber M; Leffler DA
Am J Gastroenterol; 2020 Nov; 115(11):1821-1829. PubMed ID: 33156101
[TBL] [Abstract][Full Text] [Related]
28. The burden of chronic pain for patients with osteoarthritis in Germany: a retrospective cohort study of claims data.
Schild M; Müller U; von Schenck U; Prieur S; Miller R
BMC Musculoskelet Disord; 2021 Mar; 22(1):317. PubMed ID: 33789636
[TBL] [Abstract][Full Text] [Related]
29. Burden of Herpes Zoster Among Patients with Psoriatic Arthritis in the United States.
Singer D; Thompson-Leduc P; Ma S; Gupta D; Cheng WY; Sendhil SR; Sundar M; Hagopian E; Stempniewicz N; Duh MS; Poston S
Psoriasis (Auckl); 2024; 14():63-78. PubMed ID: 38939905
[TBL] [Abstract][Full Text] [Related]
30. Epidemiology, healthcare resource utilization and healthcare costs for spinal muscular atrophy in Alberta, Canada.
Chen G; Sharif B; Gerber B; Farris MS; Cowling T; Cabalteja C; Wu JW; Maturi B; Klein-Panneton K; Jean K Mah
J Med Econ; 2021 Nov; 24(sup1):51-59. PubMed ID: 34906030
[TBL] [Abstract][Full Text] [Related]
31. Characterizing the real-world economic burden of metastatic castration-sensitive prostate cancer in the United States.
Kaye DR; Khilfeh I; Muser E; Morrison L; Kinkead F; Lefebvre P; Pilon D; George D
J Med Econ; 2024; 27(1):381-391. PubMed ID: 38420699
[TBL] [Abstract][Full Text] [Related]
32. The Economic Burden of Eosinophilic Gastritis and Eosinophilic Enteritis in the United States.
Woolley M; Cook EE; Mu F; Betts KA; Billmyer E; Yim E; Chen J; Wu EQ
Adv Ther; 2022 Aug; 39(8):3547-3559. PubMed ID: 35689161
[TBL] [Abstract][Full Text] [Related]
33. Economic and clinical burden of chronic corticosteroid use in patients with Crohn[apos]s disease initiated on biologic or conventional therapies in the US: A retrospective claims study.
Zhdanava M; Zhao R; Manceur AM; Ding Z; Boudreau J; Kachroo S; Kerner C; Izanec J; Pilon D
J Am Pharm Assoc (2003); 2024; 64(2):386-394.e10. PubMed ID: 37956768
[TBL] [Abstract][Full Text] [Related]
34. Healthcare resource utilization and cost among individuals with late-onset versus adult-onset Huntington's disease: a claims‑based retrospective cohort study.
To TM; Ta JT; Patel AM; Arndorfer S; Abbass IM; Gandhy R
J Med Econ; 2023; 26(1):862-870. PubMed ID: 37350423
[TBL] [Abstract][Full Text] [Related]
35. Healthcare costs of NVAF patients treated with rivaroxaban and apixaban in the US.
Milentijevic D; Germain G; Laliberté F; Bookhart BK; MacKnight SD; Tsang J; Lefebvre P
J Med Econ; 2020 Nov; 23(11):1365-1374. PubMed ID: 32897766
[TBL] [Abstract][Full Text] [Related]
36. Treatment patterns, health resource utilization and costs among central precocious puberty patients treated with leuprolide or histrelin: an examination of the commercial and Medicaid populations.
Klein KO; Soliman AM; Bonafede M; Nelson JK; Grubb E
J Med Econ; 2020 Apr; 23(4):407-414. PubMed ID: 31766907
[No Abstract] [Full Text] [Related]
37. Healthcare Resource Utilization and Cost of Care in Patients With Periocular Basal Cell Carcinoma: A Real-World Study.
Kahana A; Bartley K; Meyer CS; Seetasith A; Lee J; McKenna E
Am J Ophthalmol; 2022 Apr; 236():164-171. PubMed ID: 34695403
[TBL] [Abstract][Full Text] [Related]
38. Health Outcomes Among Patients Diagnosed with Schizophrenia in the US Veterans Health Administration Population Who Transitioned from Once-Monthly to Once-Every-3-Month Paliperidone Palmitate: An Observational Retrospective Analysis.
Patel C; El Khoury A; Huang A; Wang L; Baser O; Joshi K
Adv Ther; 2019 Oct; 36(10):2941-2953. PubMed ID: 31396809
[TBL] [Abstract][Full Text] [Related]
39. Real-World Characteristics, Treatment Patterns, Health Care Resource Use, and Costs of Patients with Diffuse Large B-Cell Lymphoma in the U.S.
Yang X; Laliberté F; Germain G; Raut M; Duh MS; Sen SS; Lejeune D; Desai K; Armand P
Oncologist; 2021 May; 26(5):e817-e826. PubMed ID: 33616256
[TBL] [Abstract][Full Text] [Related]
40. Healthcare Costs in Men with Metastatic Castration-Resistant Prostate Cancer: An Analysis of US Medicare Fee-For-Service Claims.
Freedland SJ; Davis MR; Epstein AJ; Arondekar B; Ivanova JI
Adv Ther; 2023 Oct; 40(10):4480-4492. PubMed ID: 37531024
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
